Probing the pathology of SARS-CoV-2 through the nearly exclusive lens of its replication and its replication receptor, ACE2, has resulted in the noted significant oversights concerning opportunities and risks of COVID-19 therapeutics. The gene discussed is ACE2; the disease is COVID-19.